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Abstract: Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urological 
malignancies and has been associated with poor responses to conventional cytotoxic chemo-
therapy. Interferon-α and interleukin-2 were previously utilized in a limited number of patients 
with good performance status due to toxicity and safety issues. Over the last decade, through 
advances in the understanding of the biology and pathology of RCC, the important role of vascular 
endothelial growth factor (VEGF) in RCC has been identified. Data from randomized trials have 
led to the approval of first-generation tyrosine kinase inhibitors (TKIs) sorafenib, sunitinib, and 
pazopanib; however, these agents inhibit a wide variety of kinase targets and are associated with 
a range of adverse effects. More recently, a new generation TKI, axitinib, has been approved by 
the US Food and Drug Administration. Tivozanib is a novel TKI, which is a potent inhibitor of 
VEGF-1, VEGF-2, VEGF-3, c-kit, and PDGR kinases, with a more restricted target spectrum. 
Phase II and III studies have demonstrated significant activity and a favorable safety profile as 
an initial targeted treatment for advanced RCC. This review examines the emerging data with 
tivozanib for the treatment of advanced RCC. Preclinical investigations as well as Phase I, II, 
and III data are examined; data on the comparative benefits of tivozanib are reviewed. Finally, 
we discuss the future potential of tivozanib in combination, biomarkers associated with tivozanib 
response, and acquisition of resistance and nonkidney cancer indications.
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Introduction
Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies 
and 90%–95% of all malignant kidney tumors. On January 1, 2009, in the United 
States, there were approximately 320,182 men and women alive who had a history 
of cancer of the kidney and renal pelvis. It is estimated that 64,770 men and women 
(40,250 men and 24,520 women) were diagnosed with, and 13,570 men and women 
died of cancer of the kidney and renal pelvis in 2012.1,2
RCC is an aggressive malignancy compared to other urological malignancies;3 
20%–30% of patients present with metastatic disease due to the insidious nature of 
the disease and absence of a screening test.4 Approximately 25% of patients with 
early-stage disease at diagnosis relapse after nephrectomy.5 Patients with advanced 
disease have a 5-year survival rate of 10%, compared to 85% for patients with localized 
RCC. Therefore, advanced RCC has been associated with a poor prognosis and poor 
responses to conventional cytotoxic chemotherapy. Immunotherapy with high-dose 
interleukin (IL)-2 or interferon-alpha (INF-α) has been used as therapy in select patients 
with good performance status. The response rate with immunotherapy is relatively 
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low (5%–30%), and toxicity and safety issues often limit 
their use.6–8 The clinical efficacy of INF- α is limited; a meta-
analysis reviewed data from 463 patients with advanced 
RCC who were administered INF-α as first-line systemic 
therapy and suggested that treatment with INF-α provides a 
median progression-free survival (PFS) of 4.7 months and a 
median overall survival (OS) of 13 months.9 In the cytokine 
era, this result was proposed as a benchmark for the future 
targeted therapies.9,10
Advances in the understanding of the biology and 
pathology of RCC identified the important role of 
vascular endothelial growth factor (VEGF). This has led 
to development of numerous targeted agents, which have 
established a new benchmark for PFS and OS in Phase III 
trials compared with INF-α.11–13 Data from randomized 
trials have led to the approval of seven agents over the last 
5 years for advanced RCCs in first- or second-line treatment 
in metastatic RCC: sunitinib, sorafenib, bevacizumab (with 
or without INF-α), temsirolimus, everolimus, pazopanib, 
and axitinib.14 Unfortunately, the existing treatment options 
have several restrictions: durable responses are rare; some 
cases show no response; the median prolongation in PFS 
is generally measured in months; and in some responding 
patients, toxicities can make long-term treatment difficult 
or necessitate dose reductions and interruptions. Because of 
these issues, additional therapies are still needed. Tivozanib 
(AV-951) is a novel agent that is a potent inhibitor of 
VEGF-1, VEGF-2, VEGF-3, c-kit, and PDGR kinases. 
Phase II and III studies have demonstrated significant activity 
and favorable safety profile as initial targeted treatment for 
advanced RCC.15,16
Molecular biology of RCC
The biology of hereditary renal neoplasms has led to a better 
understanding of the molecular basis of clear cell RCC. The 
Von Hippel–Lindau (VHL) tumor suppressor gene, located 
on chromosome 3p25, is mutated in patients with hereditary 
VHL syndrome, inducing cysts and tumors in the central 
nervous system and abdomen such as hemangioblastoma 
and pheochromocytoma. This condition also includes a 
predisposition to the development of clear cell RCC.17 
Interestingly, VHL gene inactivation has also been observed in 
84% to 98% of sporadic RCCs based upon specific mutations 
or epigenetic gene silencing.18–24 Thus, VHL abnormalities are 
key in the pathogenesis of clear cell RCC.
VHL protein regulates normal cellular responses to 
hypoxia by ubiquitin-mediated hypoxia-inducible factor 1 
alpha (HIF1alpha). Using normal oxygen levels, oxygen 
content in the blood controls the formation of VHL protein 
complexes, by targeting HIF1alpha for deprivation by 
proteasomes. Low oxygen conditions lead to HIF1alpha 
accumulation and bind to HIF1beta, followed by formation 
of a complex that transcriptionally activates genes. Similarly, 
mutation or inactivation of the VHL protein disrupts the 
ability to degrade HIF1alpha, causing excessive accumulation 
even under normal oxygen conditions. This abnormal 
response activates the hypoxia response pathway and 
galvanizes numerous HIF-responsive genes, which leads to 
overproduction of proangiogenic factors, including growth 
factors such as VEGF, platelet-derived growth factor (PDGF), 
and transforming growth factor alpha/beta. HIF accumulation 
also takes place with activation of the mammalian 
target of rapamycin (mTOR) through cellular stimuli 
and the phosphoinositide 3-kinase/Akt (protein kinase) 
pathway.25 Activated mTOR also leads to a cascade of events 
such as phosphorylation of 4E binding protein-1, leading 
to eukaryotic initiation factor-4 subunit E enhancing the 
translation of mRNAs that encode cell-cycle regulators such 
as cyclin D1 and c-myc.26,27 Sulzbacher et al28 documented 
PDGF expression in a large number of RCCs. PDGF receptor 
expression was correlated with higher in highly malignant 
tumors and adverse outcomes for patients with RCC. These 
pathways are involved in tumor proliferation,29–32 as well as 
in promoting tumor-associated angiogenesis.33
VEGF primarily affects vascular endothelial cells by 
binding to and activating three structurally similar receptor 
tyrosine kinases:30 VEGFR1 (also known as FLT1), VEGFR2 
(also known as KDR), and VEGFR3 (also known as FLT4). 
Each VEGF ligand has a specific binding affinity for each 
of these tyrosine kinase receptors, which contributes to their 
diversity. Therefore, binding of each VEGFR tyrosine kinase 
activates a distinct downstream pathway that leads to diverse 
effects that leads to tumor proliferation and metastasis by 
mediating numerous changes within the tumor vasculature 
and promoting tumor angiogenesis.18,33 Tumor angiogenesis 
is enhanced through increasing blood flow by promoting 
endothelial cell proliferation and survival; enhancing migration 
of endothelial cells; and increased permeability of existing 
cellular transport channels, developing an environment for 
endothelial cell migration through boosting chemotaxis of 
bone marrow derived endothelial cell precursors.18,34–36
Inhibition of VEGF in renal 
cell carcinoma
The inhibition of VEGF signaling may affect tumor growth 
through several mechanisms, such as antiangiogenic effects, 
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induction of endothelial cell apoptosis, and blockade of 
migration of hematopoietic and endothelial progenitor cells. 
The angiogenesis in RCC, in both the primary and metastatic 
sites of disease, is presumed to be highly VEGF-dependent 
due to the high-frequency inactivation of the VHL tumor 
suppressor gene. Therefore, VEGF has been an important 
target in development of therapeutic agents in RCC.
RCC is one of the most immunogenic tumors.5,37 
Programmed cell death 1 is one of these immunogenic 
mechanisms. BMS-936558, a monoclonal antibody directed 
at the programmed cell death 1 T-cell coinhibitory receptor, 
has been investigated in a Phase I study. In the RCC 
cohort, nine of 33 patients had an objective response.38 
Another monoclonal antibody, BMS-936559, targeting 
programmed cell death 1 ligand protein, is also being studied 
(ClinicalTrials.gov identifier: NCT01354431).39 In the 
tumor microenvironment, VEGF weakens the host immune 
response by reducing dendritic cell differentiation and 
increasing secretion of immunosuppressive cytokines such 
as IL-10 and transforming growth factor beta.34 Therefore, 
VEGF-inhibitors may also take part in modulation of the 
antitumor immunity.40
VEGF-targeted agents include bevacizumab, a humanized 
monoclonal antibody that inhibits VEGF A, and receptor 
tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, 
pazopanib, and axitinib.29,41 These agents target the VEGF 
receptors, as do additional TKIs in ongoing clinical 
development. Amongst the three receptors for VEGF, 
VEGFR-2 on endothelial cells appears to be the key target.42 
This model initiated the development of novel agents with 
enhanced targeting of VEGFR2, such as tivozanib.
Preclinical investigations 
and tivozanib pharmacology
Tivozanib is a quinoline–urea derivative, a small molecule 
recently developed as a third-generation VEGF receptor 
TKI.43 In preclinical studies, oral administration of tivozanib 
to athymic rats decreased the microvessel density within 
tumor xenografts and reduced VEGFR-2 phosphorylation 
levels in tumor endothelium, triggering inhibition of 
angiogenesis and vascular permeability. It also demonstrated 
antitumor activity in several human tumor xenografts, 
including lung, breast, colon, ovarian, pancreas, and prostate 
cancer. Preclinical activity for tivozanib in colorectal 
cancer was demonstrated by inhibition of progression in the 
peritoneal cavity in a colon cancer model with reduced tumor 
angiogenesis, ascites formation, and tumor spread, thereby 
prolonging survival.44
The activity of tivozanib has been assessed against 
several receptor tyrosine kinases using either cell-free kinase 
assays or the inhibition of ligand-induced phosphorylation of 
growth factor receptors. Tivozanib is a potent and selective 
VEGFR TKI with the highest potency for VEGFR-2, with 
similar levels for VEGFR-1 and VEGFR-3 (Table 1). 
Tivozanib showed relatively less inhibitory activity of c-kit, 
PDGF receptor (PDGFR)-b, Flt-3, fibroblast growth factor 
receptor-1, and c-met. Tivozanib has virtually no activity for 
EGFR and insulin-like growth factor-1. The specific potency 
of tivozanib on VEGFR-2 provides a theoretical distinction 
compared to earlier drugs used in RCC treatment such as 
sorafenib, sunitinib, and pazopanib.
Multitargeted TKIs may have a theoretical advantage 
of increased antitumor activity and delaying resistance; 
however, off-target effects may contribute to adverse events. 
Hand–foot syndrome, skin rash, fatigue, stomatitis, diarrhea, 
pigmentation changes, myelosuppression, and thyroid 
dysfunction are commonly associated with multitargeted 
TKI treatments.10,45 Low potency of first-generation TKIs 
requires administration of higher doses to obtain optimal 
VEGFR inhibition. This usually leads to off-target toxicities 
at therapeutic doses. Compared with other US Food and Drug 
Administration-approved small-molecule TKIs, tivozanib is 
relatively specific for VEGFR-1, VEGFR-2, and VEGFR-
3, although it still exhibits PDGFR-b inhibition. Although 
IC50 determination can be variable, depending on the cell 
system used, the IC50 concentrations for tivozanib inhibiting 
VEGFRs are the lowest in this group of agents (Table 1).
Phase I studies
Prior pharmacokinetic analysis in healthy volunteers 
demonstrated good oral bioavailability, slow absorption, 
predominantly fecal excretion, and long half-life. In this 
study, the half-life was 4.7 days, suggesting suitability for 
once-daily dosing.46 Concentration–time profiles from the 
Table 1 Receptor tyrosine kinase inhibitory activity at 50% of US 
Food and Drug Administration-approved TKIs in cell-free kinase 
assay (IC50)
TKI Tivozanib Axitinib Sunitinib Pazopanib Sorafenib
vEGFR-1 30 ND 21 7 9
vEGFR-2 6.5 0.2 34 15 28
vEGFR-3 15 ND 3 2 7
PDGFR-B 49 1.6 75 215 1129
c-Kit 78 1.7 40 48 1862
FGFR-1 530 ND 437 80 64
Abbreviations: c-Kit, stem cell factor receptor; FGFR, fibroblast growth factor 
receptor;  IC50,  half-maximal  inhibitory  concentration;  ND,  not  determined; 
PDGFR-B,  platelet-derived  growth  factor  receptor,  beta;  TKI,  tyrosine  kinase 
inhibitors; vEGFR, vascular endothelial growth factor.
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majority of patients showed secondary peaks, indicating 
that tivozanib may undergo enterohepatic recirculation, 
which would likely be a contributing factor in the observed 
long t1/2.
The first-in-human Phase I and pharmacologic study of 
tivozanib was conducted in 41 patients with advanced solid 
tumors,47 including nine subjects with RCC. Tivozanib was 
administered at dose levels of 1.0 mg, 1.5 mg, and 2.0 mg 
per day for 28 days, followed by a 14-day break. The initial 
2 mg dose produced dose-limiting toxicity, with grade 3 
proteinuria, hypertension, and ataxia. At the 1.5 mg dose level 
of tivozanib, hypertension was the most common adverse 
event (62% grade 3, 0% grade 4). Among the other grade 1 or 2 
adverse events, dysphonia was seen in 56% and diarrhea in 
31% of patients. Laboratory abnormalities included a low 
percentage of grade 3/4 liver function abnormalities and 
the absence of proteinuria. This study suggested a similar 
side effect spectrum to other oral VEGFR inhibitors. In 
another Phase II study, investigators administered tivozanib 
1.5 mg/day with a dosing schedule of 3 weeks on, 1 week 
off. Pharmacokinetic analysis and toxicity assessment was 
performed, and the results were consistent with those from 
previous tivozanib Phase I pharmacokinetic data in patients 
with advanced solid tumors and in healthy patients with no 
excess toxicity or drug accumulation.16,48,49 On that basis, the 
schedule of tivozanib 1.5 mg daily for 3 weeks followed by a 
1-week break was adopted and used in all studies since.
Plasma levels of VEGF-A and soluble VEGFR-2 showed 
dose-dependent increases and decreases, respectively. 
Partial response was observed in two of nine patients with 
RCC. Six patients had stable disease and one patient disease 
progression.47 Subsequent evaluation of pharmacokinetic 
and toxicity in early studies suggested that a dosing regimen 
of 3 weeks on then 1 week off might be more optimal than 
4 weeks on and 2 weeks off. Hence, this schedule was 
explored in the subsequent Phase II study.
Phase II study
The first Phase II trial of tivozanib enrolled 272 patients with 
a random discontinuation design for patients with stable 
disease; 83% had RCC with a clear cell component, 73% 
had undergone nephrectomy, and 46% had received prior 
therapy. Tivozanib was administered at a dose of 1.5 mg 
daily for 3 weeks, followed by a 1-week rest (3/1 week 
schedule). Median treatment duration was 8.5 months, while 
median PFS was 11.7 months (95% confidence interval 
[CI], 8.3 to 14.3 months) with an overall response rate of 
24% (95% CI, 19%–30%). Subgroup analysis was also 
conducted to explore the effect of prior therapy, but there 
was no significant difference in PFS between patients who 
had had received prior therapy and those who were treatment 
naïve. The adverse events related to tivozanib were similar to 
those observed in the Phase I trial: hypertension (45%) and 
dysphonia (21%).16,48,50
In the randomized discontinuation trial phase of the trial, 
118 patients with stable disease were randomized to either 
tivozanib or a placebo. After 16 weeks of initial therapy, 
patients were allocated to further therapy based on the 
response. Patients with more than 25% tumor regression were 
continued on tivozanib, while patients with more than 25% 
tumor progression stopped therapy. Those patients judged to 
have stable disease were then randomized in a double-blind 
fashion to continue tivozanib or placebo for 12 weeks. In this 
group, the median PFS was longer for patients continuing 
tivozanib (n = 61; 10.3 months) compared to the placebo 
group (n = 57; 3.3 months). The data for all patients entered 
is summarized in Tables 2 and 3.
In summary, the results of this trial showed that tivozanib 
was active and well tolerated in patients with advanced 
RCC. The adverse event profile was acceptable and similar 
to those seen with other VEGFR inhibitors, including 
hypertension.16
Phase III trials
In TIVO-1, a Phase III randomized, open-label, multicenter 
trial, 517 patients with clear cell advanced RCC, with prior 
nephrectomy and Eastern Cooperative Oncology Group 
performance status 0 or 1, were enrolled. Patients were 
treatment naïve or received no more than one prior systemic 
therapy for metastatic disease; those who were previously 
treated with VEGF- or mTOR-targeted therapy were 
excluded. Patients were randomized 1:1 to tivozanib 1.5 mg 
Table 2 Overall radiologic response to tivozanib among patient 
subgroups
Patient 
group
Patient 
number
Median PFS 
(months)
ORR (%) Duration 
of response 
(months)
All patients 272 11.7 
(95% CI, 
8.3–14.3)
24 
(95% CI, 
19–30)
16.1 
(95% CI, 
9.3–19.6)
Clear cell RCC 226 12.5 
(95% CI, 
9.0–17.7)
26 
(95% CI, 
19–30)
17.8 
(95% CI, 
12.0–21.0)
Clear cell RCC 
and prior 
nephrectomy
176 14.8 
(95% CI, 
10.3–19.2)
30 
(95% CI, 
23–37)
16.1 
(95% CI, 
11.2–19.6)
Abbreviations:  CI,  confidence  interval;  ORR,  objective  response  rate;  PFS, 
progression-free survival; RCC, renal cell carcinoma.
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once daily for 3 weeks on, 1 week off, or to sorafenib 400 mg 
twice daily continuously. Patients with protocol-defined 
progression on sorafenib were provided with tivozanib on 
an extension protocol; the design did not call for crossover 
from tivozanib to sorafenib as progression. Median PFS 
was 11.9 months for tivozanib, compared to 9.1 months for 
sorafenib (hazard ratio [HR], 0.797; 95% CI, 0.639–0.993; 
P = 0.042). In the treatment-naïve subgroup, the median 
PFS was 12.7 months for tivozanib and 9.1 months for 
sorafenib (HR, 0.756; 95% CI, 0.580–0.985; P = 0.037). 
OS trended in favor of sorafenib (stratified HR, 1.245; 
95% CI, 0.954–1.624; P = 0.105). Tivozanib demonstrated 
significant improvement in PFS and ORR compared with 
sorafenib as initial targeted treatment for advanced RCC. The 
safety profile of tivozanib was favorable, with significantly 
less hand–foot syndrome (13% versus 54%), diarrhea (22% 
versus 32%), and alopecia (2% versus 21%) compared 
to sorafenib. Hypertension (44% versus 34%), back pain 
(14% versus 7%), and dysphonia (21% versus 5%) were 
significantly more common in the tivozanib arm.15
In the extension study, patients with progressive disease 
(PD) on sorafenib and patients with PD on tivozanib received 
subsequent treatment. Of the 257 patients on sorafenib, 155 
(60.3%) were treated with next-line tivozanib at the time 
of the analysis. At the time of final OS analysis, which was 
2 years after the last patient was enrolled, 118 deaths had 
occurred in the tivozanib arm (45.4%) compared to the 
sorafenib arm, where 101 deaths occurred (39.3%). There 
was no significant difference in OS between the two treatment 
arms (28.8 months for tivozanib versus 29.3 months for 
sorafenib). After discontinuation of initial therapy, 64% of 
patients in the tivozanib arm received no next-line therapy, 
compared with 26% of patients in the control arm. The 
authors suggested that the high rate of utilization of second-
line tivozanib in patients following PD on sorafenib might 
have affected the OS outcome.51 The key additional factor in 
this trial was that patients, many of whom resided in Eastern 
Europe, initially received tivozanib but had limited access 
to additional targeted therapies with efficacy in metastatic 
RCC.15 This meant that those initially given sorafenib 
received two drugs, compared to the one drug administered 
to those given tivozanib.
In the Phase II extension study of tivozanib for patients 
crossing over from sorafenib, RCC patients who were 
treated with tivozanib after progression on sorafenib were 
evaluated. Partial response (PR) was 7.9%; stable disease 
(SD) was 65.4%, and 71.3% of patients showed some degree 
of tumor shrinkage. Median duration of PR, SD, and PFS 
was 11.1 months (95% CI, 7.5–not reported [NR] months), 
12.7 months (95% CI, 7.4–NR months), and 5.6 months 
(95% CI, 5.4–9.1 months), respectively. The preliminary 
data demonstrated that tivozanib has antitumor activity after 
PD on sorafenib. The adverse event profile of tivozanib after 
sorafenib was similar to that observed in TIVO-1.52
The subgroup analysis from TIVO-1 showed significant 
improvement in PFS by tivozanib compared to sorafenib. The 
PFS advantage was observed in those patients who were of 
Caucasian descent, had an Eastern Cooperative Oncology 
Group performance status of 0, who were diagnosed more 
than 1 year prior, who had received no prior treatment, who 
had more than 2 metastatic sites, whose baseline systolic 
blood pressure (BP) was greater than 140 mmHg, and whose 
baseline diastolic BP was less than 90 mmHg. Patients who 
developed hypertension during the study had significantly 
longer PFS than patients with normal BP. The improvement 
in PFS was more marked for tivozanib compared to sorafenib 
for the patients who developed hypertension.53 Similar 
results were previously reported by Rini et al54 in patients 
with metastatic RCC, whereby sunitinib-associated HTN is 
associated with improved clinical outcomes.
Health-related quality of life assessment was generally 
similar for tivozanib and sorafenib. The physical well-being 
assessment demonstrated more significant improvement with 
tivozanib compared to sorafenib.55 The data for Phase III 
trials utilizing VEGF inhibitors or VEGF antibodies in 
advanced RCC are summarized in Tables 4 and 5.
Future aspects
Tivozanib will be compared to sunitinib in the TAURUS 
trial, a first-line randomized Phase II patient preference 
trial in metastatic RCC. In this trial design (modeled on the 
PISCES trial, which compared pazopanib and sunitinib), 
patients are randomized to either tivozanib or sunitinib for 
Table 3 Adverse events and laboratory abnormalities
Adverse event All grades (%) Grade 1/2 (%) Grade 3/4 (%)
Hypertension 45 31 12
Dysphonia 22 22 0
Asthenia 10 7 3
Diarrhea 12 10 2
Fatigue 8 6 2
Hand–foot 
syndrome
4 4 ,1
Stomatitis 4 6 ,1
ALT elevation 29 28 1
AST elevation 27 26 1
Direct bilirubin 24 22 2
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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12 weeks, followed by a restaging and toxicity assessment 
and crossover to the other drug for 12 weeks. Patients are 
then reassessed and state a preference for either drug.
Combination therapies in RCC
Currently approved targeted therapy improved PFS and 
OS in advanced RCC; however, durable responses are 
infrequent, and resistance is commonly seen after a median of 
6–15 months.56 Despite maximal inhibition of VEGF/VEGFR 
and PDGF/PDGFR pathways, resistance reliably develops 
due to a process known as “reactive resistance.” There are two 
major models that explain the resistance to VEGF inhibitors, 
which are adaptive and intrinsic. The adaptive mechanism of 
resistance hypothesizes that tumors elude the VEGF inhibitor 
effects and salvage their functionality through an escape 
mechanism.57 In preclinical models, HIF1alpha and HIF2alpha 
are major mediators of this process.58,59 In a xenograft 
model, it was shown that increased IL-8 was consistent 
with escape from antiangiogenic agents. Administration of 
IL-8 neutralizing antibody successfully sensitized tumors 
to sunitinib, which supported this hypothesis.60 Increased 
placental growth factor levels, angiopoietin pathway, and 
PDGFR have been associated with emergence of alternative 
proangiogenic mechanisms that would lead to resistance.61–64 
Intrinsic resistance defines the types of tumors that would 
not respond to VEGF inhibitors under any circumstances. 
This mechanism has been only shown in animal models.65 
Tumors that are driven by this pathway develop progressive 
disease soon after VEGF inhibitor treatment has been started. 
However, given that pathways other than VEGF or mTOR 
play a role in tumorigenesis,57 other pathways may also be 
related to resistance to VEGF or mTOR-targeted therapy in 
RCC. For instance, basic fibroblast growth factor, hepatocyte 
growth factor, and IL-6 have recently been shown to increase 
Table 4 Phase III trials utilizing vEGF inhibitors or vEGF antibodies in advanced RCC survival and toxicity data
Trial Arms N MSKCC 
prognostic risk:76 
Favorable 
Intermediate 
Poor
Toxicity all grades† OS 
PFS 
ORR (CR + PR) 
CR
Motzer et al15,51,77 
Phase III
Tivozanib 
Sorafenib
260 
257
27% versus 34% 
67% versus 62% 
7% versus 4%
Diarrhea 
Fatigue 
HFS 
HTN
22% 
18% 
13% 
44%
28.8 versus 29.3 months 
11.9 versus 9.1 months 
33% versus 23% 
1% versus 1%
Escudier et al78 
Phase III
Sorafenib 
Placebo
451 
452
NR 
48% versus 49% 
52% versus 50%
Diarrhea 
Fatigue 
HFS 
HTN
43% 
37% 
30% 
2%
19.3 versus 15.9 months 
5.5 versus 2.8 months* 
11% versus 2%* 
,1% versus 0%
Motzer et al11 
Phase III
Sunitinib 
INF-α
375 
375
38% versus 34% 
56% versus 59% 
6% versus 7%
Diarrhea 
Fatigue 
HFS 
HTN
53% 
51% 
20% 
24%
26.4 versus 21.8 months 
11 versus 5 months* 
47% versus 12%* 
0% versus 0%
Escudier et al79 
Phase III
Bevacizumab + INF-α 
Placebo + INF
327 
322
27% versus 29% 
56% versus 56% 
9% versus 8%
Diarrhea 
Fatigue 
HFS 
HTN
20% 
33% 
NR 
26%
23.3 versus 21.3 months 
10.2 versus 5.4 months* 
31% versus 13%* 
1% versus 2%
Rini et al80 
Phase III
Bevacizumab + INF-α 
INF
369 
363
26% versus 26% 
64% versus 64% 
10% versus 10%
Diarrhea 
Fatigue 
HFS 
HTN
NR 
93% 
NR 
28%
18.3 versus 17.4 months 
8.5 versus 5.2 months* 
13% versus 9% 
,1% versus ,1%
Sternberg et al81 
Phase III
Pazopanib 
Placebo
290 
145
39% versus 39% 
55% versus 53% 
3% versus 3%
Diarrhea 
Fatigue 
HFS 
HTN
52% 
40% 
,10% 
40%
22.9 versus 20.5 months 
9.2 versus 4.2 months* 
30% versus 3%* 
,1% versus 0%
Rini et al82 
Phase III
Axitinib 
Sorafenib
361 
362
28% versus 28% 
37% versus 36% 
33% versus 33%
Diarrhea 
Fatigue 
HFS 
HTN
55% 
39% 
27% 
40%
Not reported 
6.7 versus 4.7 months* 
19% versus 9%* 
0% versus 0%
Notes: *Not significant; †toxicity for agent in the intervention arm.
Abbreviations: CR, complete response; HFS, hand–foot syndrome; HTN, hypertension; INF, interferon; MSKCC, Memorial Sloan-Kettering Cancer Center; N, number; 
NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; RCC, renal cell carcinoma; VEGF, vascular 
endothelial growth factor.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
144
Hepgur et alBiologics: Targets and Therapy 2013:7
or remain high immediately before progression in patients 
being treated with sunitinib.66
Because the activation of multiple parallel pathways leads 
to VEGF resistance, investigators have postulated that adding 
inhibitors of other pathways might mitigate resistance and 
improve outcome.
Given significant activity in RCC, mTOR inhibitors and 
VEGF inhibitors are an obvious potential combination to 
provide targeted inhibition tumor cell growth via parallel 
and overlapping pathways in the context of different side 
effect profiles.41 Previously tested combinations of mTOR 
inhibitors with sunitinib or sorafenib were either not 
tolerated or tolerated at attenuated doses due to adverse 
event profile.67,68 More recently, the TORAVA randomized 
Phase II trial assessing the safety profile and efficacy of 
bevacizumab and temsirolimus demonstrated a worse 
toxicity profile and poorer disease control than sunitinib.69 In 
contrast, a Phase I study of the combination of everolimus and 
sorafenib at submaximal doses produced acceptable toxicity 
and evidence of antitumor activity in previously untreated 
patients with metastatic RCC.70
Tivozanib was combined with temsirolimus in a Phase IB 
study. In contrast to other combinations, the authors reported 
that full doses of tivozanib (1.5 mg/day) and temsirolimus 
(25 mg/week) were tolerable, with no dose-limiting toxicities. 
Activity in terms of prolonged stable disease and partial 
response was reported in subjects on the trial. These results 
are promising, since tivozanib was the first selective VEGFR 
TKI to be successfully combined with an mTOR inhibitor at 
the full recommended dose and schedule of both agents.71,72 
Table 5 Phase III trials utilizing vEGF inhibitors or vEGF antibodies in advanced RCC discontinuation data
Trial Arms N Reasons to discontinue therapy
PD or death  Toxicity Patient choice
N % N % N %
Motzer et al15,77 
Phase III
Tivozanib 
Sorafenib
260 
257
189 
226
72 
87
4 
5
1 
2
NR
NR
NR
NR
Escudier et al78 
Phase III
Sorafenib 
Placebo
451 
452
246 
300
55 
66
18 
17
4 
4
7 
11
2 
2
Motzer et al11 
Phase III
Sunitinib 
INF-α
375 
375
92 
170
25 
45
30 
47
8 
13
4 
16
1 
4
Escudier et al79 
Phase III
Bevacizumab + INF-α 
Placebo + INF-α
327 
322
151 
224
46 
70
86 
32
26 
10
10 
11
10 
11
Rini et al80 
Phase III
Bevacizumab + INF-α 
INF-α
369 
363
200 
218
54 
60
85 
66
23 
18
40 
33
11 
3
Sternberg et al81 
Phase III
Pazopanib 
Placebo
290 
145
158 
121
54 
83
41 
5
14 
3
18 
4
6 
4
Rini et al82 
Phase III
Axitinib 
Sorafenib
361 
362
172 
193
48 
53
22 
33
6 
9
10 
7
3 
2
Abbreviations: INF, interferon; N, number; NR, not reported; PD, progressive disease; RCC, renal cell carcinoma; vEGF, vascular endothelial growth factor.
A recent study has demonstrated activity of tivozanib after 
treatment with VEGF inhibitors, specifically sorafenib.52 
Additional studies are warranted to determine whether 
tivozanib, alone or in combination, may be effective after 
resistance to other VEGF-targeted drugs develops.
Nonkidney cancer clinical development 
directions with tivozanib
Tivozanib is also currently being evaluated in patients with 
other cancer types and demonstrated promising results. 
Phase I studies showed that tivozanib can be safely combined 
at full doses and schedule with paclitaxel in metastatic 
breast cancer and FOLFOX6 in advanced gastrointestinal 
tumors.49,73 A study evaluating the combination of tivozanib 
with everolimus in metastatic colorectal cancer is ongoing 
(ClinicalTrials.gov identifier: NCT01058655). In another 
open-label trial, tivozanib is being investigated in patients 
with nonsmall cell lung cancer (ClinicalTrials.gov identifier: 
NCT00826878).
Biomarkers associated 
with tivozanib response
Tumor-associated macrophages enhance immunosup-
pression and angiogenesis by secreting VEGF, cytokines, 
and other angiogenesis factors. These tumor-associated 
macrophages are regulated by myeloid-derived suppressor 
cells. Myeloid-derived suppressor cells and their secreted 
alternative ligands are associated in the development 
of resistance to bevacizumab and VEGF receptor TKI 
therapy.40
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Myeloid cells have also been investigated as a predictor of 
tivozanib efficacy. In a preclinical study to identify biomarkers 
associated with tivozanib response, a population-based tumor 
model comprising more than 100 genetically developed breast 
HER2 tumors was used to test the efficacy of tivozanib. IHC 
analysis of infiltrating myeloid cells in 21 patient samples 
demonstrated a significant correlation between the percent 
myeloid cell composition in the tumors and maximum tumor 
shrinkage by RECIST (Response Evaluation Criteria In Solid 
Tumors) criteria. The data demonstrated the presence of 
tivozanib sensitive and insensitive angiogenesis mechanisms 
in both murine and human solid tumors. These findings 
provided evidence for a potential biomarker that could be 
utilized to predict tivozanib response.36
The Phase II BATON trial was designed to further validate 
a tivozanib-resistance biomarker, as well as to determine 
the biomarkers that may predict clinical activity and/or 
toxicity with tivozanib. Investigators identified a 42-gene 
resistance signature defining a specific tumor infiltrating 
myeloid population by using a novel, coherence-based 
bioinformatics analysis of pretreatment tumor microarray 
data. They analyzed 21 samples from patients treated with 
tivozanib in a Phase II RCC trial. The data demonstrated 
that the percent of myeloid cell composition in the tumors 
and clinical antitumor activity of tivozanib was significantly 
correlated (ClinicalTrial.gov identifier: NCT01297244).74
In a more recent study, investigators characterized 
molecularly annotated datasets that were available from a 
Phase III TIVO-1 trial to further characterize molecular RCC 
subtypes and evaluate relationships between subtypes and 
VEGF TKI activity. Based on their analysis, the hypoxia 
signature was significantly associated with better PFS on 
tivozanib. The study demonstrated a distinct molecular 
profile, which can be classified by a low hypoxia signature 
and may help identify tivozanib responders.75
Conclusion
In conclusion, tivozanib is a novel TKI with relative 
selectivity for VEGF receptors compared to earlier drugs. 
Tivozanib demonstrated better response rates and PFS in a 
Phase III study in a composite group of patients who were 
therapy naïve or who had had one line of therapy, typically 
with cytokines. The safety profile of tivozanib differed from 
sorafenib with less hand–foot skin reactions and diarrhea, and 
more hypertension. Phase I data suggests that tivozanib and 
temsirolimus can be given together in full therapeutic doses, 
while other trials investigating combinations are ongoing. 
The TAURUS clinical trial is currently investigating the 
efficacy of tivozanib versus sunitinib in a first-line setting 
(ClinicalTrials.gov identifier: NCT01673386). However, 
given the target and toxicity profile of tivozanib, the setting 
in which this agent may be used to greatest advantage 
in the current RCC landscape is in first-line therapy for 
metastatic disease. A first-line Phase III trial of tivozanib 
compared to pazopanib is in its planning phase. Tivozanib 
will also be explored in other cancers including colorectal, 
lung, breast, and hepatobiliary cancers.
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